N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
AssigneePfizer Inc.
InventorsScott William Bagley, David Andrew Griffith, Daniel Wei-Shung Kung
Life of this patent
Estimating the term…
Abstract
The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
Claims8
1′-(1H-indazole-5-carbonyl)-1-isopropyl-4,6-dihydrospiro[indazole-5,4′-piperidin]7(1H)-one or a pharmaceutically acceptable salt thereof.
1-(tert-butyl)-1′-(1H-indazole-6-carbonyl)-4,6-dihydrospiro[indazole-5,4′-piperidin]-7(1H)-one or a pharmaceutically acceptable salt thereof.
A compound that is
- or a pharmaceutically acceptable salt thereof.
1-isopropyl-1′-(1H-pyrrolo[3,2-b]pyridine-2-carbonyl)-4,6-dihydrospiro[indazole-5,4′-piperidin]-7(1H)-one or a pharmaceutically acceptable salt thereof.
A compound of structure
A compound of structure
A compound of structure
A compound of structure
Dependencies are inferred from the claim text.